Oppilan Pharma
Altrincham
About Oppilan Pharma
Oppilan Pharma is a clinical-stage biopharmaceutical company focused on developing novel small molecule therapeutics for the treatment of autoimmune diseases. Oppilan Pharma's lead drug candidate, OPL-002, is a potent and selective modulator of sphingosine 1 phosphate receptor subtype 1 (S1P1) under development for the treatment of inflammatory bowel disease. The company initiated a Phase 1 clinical study with OPL-002 in December 2018.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 1 – 10
- Estimated revenue: $1K – $10K
- Total funding: $4.2M
- Last round: Series Unknown (Dec 2016)
- Website: oppilan.com
- Phone: 858-945-2393
Industries & Categories
Biotechnology, Clinical Trials, Pharmaceutical
Social Profiles
Canonical: https://fsome.com/organization/oppilan-pharma-71843 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.